24/7 Market News Snapshot 14 October, 2025 – Genprex, Inc. Common Stock (NASDAQ:GNPX)

October 14, 2025

DENVER, Colo., 14 October, 2025 (www.247marketnews.com) – (NASDAQ:GNPX) are discussed in this article.
Genprex, Inc. has observed a significant surge in its stock value, opening at $0.206 and reaching an impressive high of $0.238, reflecting a remarkable increase of 22.68% from the previous closing price of $0.194. This surge indicates a renewed investor interest bolstered by the company’s promising developments in the biotech arena, with a trading volume of 7.89 million shares being exchanged. Technical indicators are favorable, suggesting that this upward trend may persist, making Genprex a noteworthy consideration for investors seeking opportunities in groundbreaking therapeutic advancements.

In a related development, Genprex announced that preclinical data showcasing its lead therapeutic candidate, Reqorsa® Gene Therapy, will be presented at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025. This presentation emphasizes the promising efficacy of Reqorsa in targeting ALK-EML4 positive non-small cell lung cancer (NSCLC). The research, conducted in collaboration with the University of Michigan Rogel Cancer Center, highlights the gene therapy’s ability to induce apoptosis in cancer cells and aims to further explore its potential when used in combination with existing ALK inhibitors.

Ryan Confer, President and CEO of Genprex, expressed enthusiasm over the forthcoming presentation of the positive preclinical findings, affirming the potential of Reqorsa against ALK-positive lung cancer. The study underscores Genprex’s commitment to expanding treatment options for cancer and diabetes patients, showcasing its innovative non-viral Oncoprex® Delivery System. This advancement is a testament to Genprex’s mission of revolutionizing therapeutic approaches while addressing the needs of patient populations with limited alternatives. As the company continues to assert its presence in the oncology space, investors are encouraged to monitor ongoing developments closely.

Related news for (GNPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.